| Cancer therapeutics and mechanisms | Lifetime | 4 | US 3 | 99.87 |
| Lung Cancer Research Studies | Lifetime | 13 | US 9 | 99.92 |
| Lung Cancer Treatments and Mutations | Lifetime | 14 | US 10 | 99.94 |
| Myasthenia Gravis and Thymoma | Lifetime | 8 | US 5 | 99.76 |
| Colorectal Cancer Treatments and Studies | Lifetime | 38 | US 21 | 99.78 |
| Neuroendocrine Tumor Research Advances | Lifetime | 47 | US 25 | 99.68 |
| Cancer Treatment and Pharmacology | Lifetime | 104 | US 58 | 99.64 |
| HER2/EGFR in Cancer Research | Lifetime | 75 | US 41 | 99.60 |
| Peptidase Inhibition and Analysis | Lifetime | 152 | US 71 | 99.27 |
| Lung Cancer Diagnosis and Treatment | Lifetime | 150 | US 75 | 99.49 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 297 | US 167 | 99.28 |
| Cancer Genomics and Diagnostics | Lifetime | 361 | US 213 | 99.32 |
| Neuroblastoma Research and Treatments | Lifetime | 158 | US 85 | 98.87 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 133 | US 77 | 98.73 |
| Cell death mechanisms and regulation | Lifetime | 154 | US 66 | 98.68 |
| Pituitary Gland Disorders and Treatments | Lifetime | 246 | US 90 | 98.55 |
| Drug Transport and Resistance Mechanisms | Lifetime | 368 | US 153 | 98.25 |
| Cancer-related Molecular Pathways | Lifetime | 468 | US 269 | 98.36 |
| Gastric Cancer Management and Outcomes | Lifetime | 809 | US 250 | 98.44 |
| Pleural and Pulmonary Diseases | Lifetime | 232 | US 114 | 98.00 |
| Occupational and environmental lung diseases | Lifetime | 173 | US 76 | 97.88 |
| Chemotherapy-induced organ toxicity mitigation | Lifetime | 61 | US 18 | 96.75 |
| Histone Deacetylase Inhibitors Research | Lifetime | 301 | US 168 | 97.06 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | Lifetime | 715 | US 199 | 97.38 |
| Cancer Research and Treatments | Lifetime | 795 | US 420 | 96.37 |
| Ubiquitin and proteasome pathways | Lifetime | 867 | US 419 | 96.62 |
| Protein Degradation and Inhibitors | Lifetime | 573 | US 286 | 96.04 |
| Multiple Myeloma Research and Treatments | Lifetime | 788 | US 353 | 96.27 |
| Neutropenia and Cancer Infections | Lifetime | 474 | US 226 | 96.12 |
| Cancer Mechanisms and Therapy | Lifetime | 707 | US 281 | 93.54 |
| Chemotherapy-related skin toxicity | Lifetime | 625 | US 288 | 84.48 |
| Myasthenia Gravis and Thymoma | 2021-2025 | 233 | US 51 | 87.46 |
